Cellectis

The first patient completed the 28-day Dose Limiting Toxicity (DLT) observation period without complication NEW YORK,…
Read More...

Le premier patient a terminé la période d’observation (DLT) de 28 jours, sans complication NEW YORK, 22 déc. 2022…
Read More...

• AMELI-01 (evaluating UCART123) abstract, selected for oral presentation, highlights that adding alemtuzumab was…
Read More...

• L’abstract AMELI-01 (évaluant UCART123), sélectionné pour une présentation orale, montre que l’ajout d’alemtuzumab au…
Read More...

NEW YORK, 11 oct. 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de…
Read More...

NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a…
Read More...

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a…
Read More...

NEW YORK, 05 oct. 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de…
Read More...

UCART20x22 is Cellectis’ first allogeneic dual CAR T, targeting CD20 and CD22 simultaneously UCART20x22 is Cellectis’…
Read More...

Preclinical data demonstrated POC with robust in vitro and in vivo anti-tumor activity UCART20x22 allogeneic dual CAR…
Read More...